Exelixis and BioInvent Establish Exclusive Option and License Agreement to Develop Novel Antibody-Based Immuno-Oncology Therapies
ALAMEDA, Calif. & LUND, Sweden--(BUSINESS WIRE)--Jun 16, 2022--
ALAMEDA, Calif. & LUND, Sweden--(BUSINESS WIRE)--Jun 16, 2022--